Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 2, 2017
- Pharmaceutical Technology-04-02-2017
- Volume 41
- Issue 4
Mass Spectrometry System Standardizes Workflows
The X500B QTOF System is the latest solution in SCIEX’s X-Series Quadrupole Time of Flight (QTOF) mass spectrometry (MS) platform.
The X500B QTOF System is the latest solution in SCIEX’s X-Series Quadrupole Time of Flight (QTOF) mass spectrometry (MS) platform. The system was specifically developed to deliver high-resolution standardized workflows for biotherapeutic developers, who are required to fully characterize biologic products in large numbers during the development process.
The X500B QTOF System comes with BioPharmaView Software 2.0, which offers the ability to interpret SWATH 2.0 data independent acquisition on the X500B QTOF System. SWATH acquisition allows for comprehensive peptide mapping data to be acquired in an injection, with high-resolution mass spectrometry and tandem mass spectrometry data for every peptide in the sample. This strategy results in the ability to detect low-abundance peptides and post-translational modifications.
Articles in this issue
over 9 years ago
EU–US Mutual Recognition Agreement on GMP Inspectionsover 9 years ago
Evaluating Progress in Analytical Quality by Designover 9 years ago
Staffing for China’s Rapidly Growing Biomanufacturing Industryover 9 years ago
Making the Most of Internal Auditsover 9 years ago
FDA Quality Metrics Initiative Challenges Manufacturersover 9 years ago
Multi-Functional Mixing System for Pastes, Creams, and Gelsover 9 years ago
Nanoparticle Deagglomeration TechnologyRelated to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.